JACKSONVILLE, Fla.–(BUSINESS WIRE)–FIS® (NYSE: FIS), a global leader in financial technology, today announced the integration of Spade’s real-time transaction enrichment technology into FIS’s debit processing platform. The integration is designed to give FIS debit issuing clients access to richer, more precise merchant data at the transaction level and to help ensure cardholder statements reflect clearer, more recognizable merchant names. The designed result is to reduce unnecessary disputes,
Month: September 2026
JACKSONVILLE, Fla.–(BUSINESS WIRE)–FIS® (NYSE: FIS), a global leader in financial technology, today announced the integration of Spade’s real-time transaction enrichment technology into FIS’s debit processing platform. The integration is designed to give FIS debit issuing clients access to richer, more precise merchant data at the transaction level and to help ensure cardholder statements reflect clearer, more recognizable merchant names. The designed result is to reduce unnecessary disputes,
LIVONIA, Mich.–(BUSINESS WIRE)–Masco Corporation (NYSE: MAS) will hold a conference call regarding its 2026 third quarter results on Wednesday, October 28 at 8:00 a.m. ET, hosted by President and Chief Executive Officer, Jon Nudi. To join, dial (585) 542-9983 or (833) 461-5787 and enter meeting ID 284633590. Please register five to ten minutes before the call begins. The 2026 third quarter results and supporting materials will be released at 7:00 a.m. ET on October 28 and can be found on the
LIVONIA, Mich.–(BUSINESS WIRE)–Masco Corporation (NYSE: MAS) will hold a conference call regarding its 2026 third quarter results on Wednesday, October 28 at 8:00 a.m. ET, hosted by President and Chief Executive Officer, Jon Nudi. To join, dial (585) 542-9983 or (833) 461-5787 and enter meeting ID 284633590. Please register five to ten minutes before the call begins. The 2026 third quarter results and supporting materials will be released at 7:00 a.m. ET on October 28 and can be found on the
THOUSAND OAKS, Calif.–(BUSINESS WIRE)–Teledyne Technologies Incorporated (NYSE:TDY) announced today that Jason VanWees, Vice Chairman, will be retiring from his current position at Teledyne, effective February 1, 2027, at which point he will be age 55. Jason joined Teledyne prior to the company’s spin-off in 1999 and was named Vice Chairman in 2021. Mary Grace DeForest, Senior Vice President and General Manager of Teledyne Microwave, has been appointed Corporate Vice President of Investor Rel
THOUSAND OAKS, Calif.–(BUSINESS WIRE)–Teledyne Technologies Incorporated (NYSE:TDY) announced today that Jason VanWees, Vice Chairman, will be retiring from his current position at Teledyne, effective February 1, 2027, at which point he will be age 55. Jason joined Teledyne prior to the company’s spin-off in 1999 and was named Vice Chairman in 2021. Mary Grace DeForest, Senior Vice President and General Manager of Teledyne Microwave, has been appointed Corporate Vice President of Investor Rel
FOSTER CITY, Calif.–(BUSINESS WIRE)–Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
FOSTER CITY, Calif.–(BUSINESS WIRE)–Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
MUMBAI, India & CINCINNATI–(BUSINESS WIRE)–Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715; together with its subsidiaries and/or associated companies, “Sun Pharma”) and LIB Therapeutics Inc. (“LIB”) today announced: An exclusive licensing agreement granting Sun Pharma rights to commercialize and manufacture lerodalcibep worldwide, excluding the United States and China. Lyrokaul (lerodalcibep), a once-monthly PCSK9 inhibitor for LDL-C lo
MUMBAI, India & CINCINNATI–(BUSINESS WIRE)–Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715; together with its subsidiaries and/or associated companies, “Sun Pharma”) and LIB Therapeutics Inc. (“LIB”) today announced: An exclusive licensing agreement granting Sun Pharma rights to commercialize and manufacture lerodalcibep worldwide, excluding the United States and China. Lyrokaul (lerodalcibep), a once-monthly PCSK9 inhibitor for LDL-C lo